» Articles » PMID: 33241675

Inhibition of the Anti-apoptotic Protein MCL-1 Severely Suppresses Human Hematopoiesis

Overview
Journal Haematologica
Specialty Hematology
Date 2020 Nov 26
PMID 33241675
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already FDA-approved, BCL-XL and MCL-1 inhibitors are currently in early clinical trials. To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic system, we used RNAi and the small molecule inhibitor S63845 on cord blood-derived CD34+ cells. Both approaches resulted in almost complete depletion of human hematopoietic stem and progenitor cells. As a consequence, maturation into the different hematopoietic lineages was severely restricted and CD34+ cells expressing MCL-1 shRNA showed a very limited engraftment potential upon xenotransplantation. In contrast, mature blood cells survived normally in the absence of MCL-1. Combined inhibition of MCL-1 and BCL-XL resulted in synergistic effects with relevant loss of colony-forming HSPCs already at inhibitor concentrations of 0.1 μM each, indicating "synthetic lethality" of the two BH3-mimetics in the hematopoietic system.

Citing Articles

BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.

Wu Y, Zehnle P, Rajak J, Koleci N, Andrieux G, Gallego-Villar L Leukemia. 2023; 38(1):136-148.

PMID: 37945692 PMC: 10776398. DOI: 10.1038/s41375-023-02079-5.


PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia.

Shah K, Nasimian A, Ahmed M, Al Ashiri L, Denison L, Sime W Blood Cancer J. 2023; 13(1):139.

PMID: 37679323 PMC: 10484999. DOI: 10.1038/s41408-023-00914-7.


PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.

Jayappa K, Tran B, Gordon V, Morris C, Saha S, Farrington C J Clin Invest. 2023; 133(13).

PMID: 37166997 PMC: 10313372. DOI: 10.1172/JCI155938.


Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling.

Shah K, Al Ashiri L, Nasimian A, Ahmed M, Kazi J Int J Mol Sci. 2023; 24(5).

PMID: 36902436 PMC: 10003524. DOI: 10.3390/ijms24055004.


What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?.

Brinkmann K, Ng A, de Graaf C, Strasser A Cell Death Differ. 2022; 29(6):1079-1093.

PMID: 35388168 PMC: 9177562. DOI: 10.1038/s41418-022-00987-0.


References
1.
Lee E, Harris T, Tran S, Evangelista M, Arulananda S, John T . BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019; 10(5):342. PMC: 6482196. DOI: 10.1038/s41419-019-1568-3. View

2.
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno A, Le Toumelin-Braizat G . The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016; 538(7626):477-482. DOI: 10.1038/nature19830. View

3.
Souers A, Leverson J, Boghaert E, Ackler S, Catron N, Chen J . ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2):202-8. DOI: 10.1038/nm.3048. View

4.
Kozopas K, Yang T, Buchan H, Zhou P, Craig R . MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993; 90(8):3516-20. PMC: 46331. DOI: 10.1073/pnas.90.8.3516. View

5.
Veis D, Sorenson C, Shutter J, Korsmeyer S . Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 1993; 75(2):229-40. DOI: 10.1016/0092-8674(93)80065-m. View